SM
FLXN

Sabby Management’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Sabby Management’s Portfolio FLXN Stock Details FLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-341
Closed -$825K – 209
2017
Q3 		$825K Sell
341
-414
-55% -$9.73K 0.05% 86
2017
Q2 		$1.53M Buy
755
+239
+46% +$4.98K 0.1% 84
2017
Q1 		$1.39M Buy
516
+390
+310% +$7.96K 0.07% 112
2016
Q4 		$240K Buy
+126
New +$2.41K 0.01% 235

Other funds holding FLXN

GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Sabby Management's FLXN Position: Q1 2017 in Review

Sabby Management sold out of Flexion Therapeutics, Inc. (FLXN) in Q1 2017, closing a stake of 10,914 shares — an estimated $223K sold.

Sabby Management first reported a position in FLXN in Q1 2016 and held it in 4 quarters. The position peaked at $1.51M in Q2 2016. 100 funds tracked by Wall St. Rank hold FLXN as of Q1 2017.

  • Sabby Management reported no remaining Flexion Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
  • Sabby Management sold 10,914 Flexion Therapeutics, Inc. shares in Q1 2017, an estimated $223K.
  • Sabby Management first reported a position in Flexion Therapeutics, Inc. in Q1 2016 and held it in 4 quarters.
  • Sabby Management's Flexion Therapeutics, Inc. position peaked at $1.51M in Q2 2016.
  • 100 funds tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q1 2017.

Based on Sabby Management's 13F filing for Q1 2017, filed 15 May 2017.